Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

Julie Marie Vose, Philip Jay Bierman, Fausto R. Loberiza, Charles Arthur Enke, Jordan Hankins, Robert G Bociek, Wing C. Chan, Dennis D. Weisenburger, James Olen Armitage

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

The purpose of this study was to evaluate the standard outpatient dose of 131-Iodine tositumomab (75 cGy) combined with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous stem cell rescue for the treatment of chemotherapy-sensitive relapsed or refractory, or high-risk first complete remission (CR) patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL). Forty patients with chemotherapy-sensitive persistent or relapsed or high/intermediate or high international prognostic index DLCBL were treated in a phase II trial combining 75 cGy 131-Iodine tositumomab with high-dose BEAM followed by autologous stem cell transplantation. The CR rate after transplantation was 78%, and the overall response rate was 80%. Short-term and long-term toxicities were similar to historical control patients treated with BEAM alone. With a median follow-up of 6 years (range, 3-10 years), the 5-year overall survival (OS) was 72% (95% confidence interval [CI], 55%-83%), and the 5-year progression-free survival (PFS) rate was 70% (95% CI, 53%-82%). The PFS and OS were encouraging in this group of chemotherapy-sensitive persistent, relapsed, or high-risk patients with DLBCL. A follow-up phase III trial with 131-Iodine tositumomab/BEAM vs rituximab/BEAM was planned based on this information.

Original languageEnglish (US)
Pages (from-to)123-128
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2013

    Fingerprint

Keywords

  • 131-Iodine tositumomab
  • Autologous stem cell transplantation
  • Diffuse large B cell lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this